BCL2L11 and cardiomyopathy: Identification of the drug target through TPP, which was confirmed by using genetic knockouts, is consistent with our previous findings on the role of the Hippo pathway in inducing Bim and leading to cardiomyopathy (Zhao et al, 2019).